Baxter International has submitted an Investigational New Drug application for its investigational hemophilia A treatment BAX 855 with the U.S. Food and Drug Administration, following positive results from a Phase I trial. BAX 855 is a full-length longer-acting recombinant factor VIII that was developed to increase the half-life of ADVATE – the most widely chosen rFVIII in the world. Baxter expects to start enrollment of adult patients in its Phase II/III study in the first quarter of 2013.
- Pharmaceuticals & Drug Trials
- Baxter International